New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
10:15 EDTMYGNMyriad says trial date not scheduled after injunctive relief denied
Myriad Genetics confirmed earlier today that the U.S. District Court for the District of Utah denied its motion for preliminary injunctive relief. Myriad alleges that Ambry Genetics' testing services infringe various patent claims owned by the BRCA patent owners which relate to the BRCA1 and BRCA2 genes, and were seeking a preliminary injunction to prevent Ambry from selling the testing services. The company said, "We believe the BRCA patents at issue in this case are valid, enforceable and infringed, and are confident we will prevail based on the full evidence. A trial date has not been scheduled." Shares of Myriad are down 9%, or $3.58, to $34.17 in early trading.
News For MYGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2015
07:41 EDTMYGNMyriad Genetics upgraded on positive risk/reward at Wells Fargo
Subscribe for More Information
06:22 EDTMYGNMyriad Genetics upgraded to Outperform from Market Perform at Wells Fargo
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use